NASDAQ$SION
Sionna Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
Sionna Therapeutics reported Q2 2025, net loss of $18.1M, diluted EPS of $-0.35.
For Q2 2025, Sionna Therapeutics reported a net loss of $18.1M, diluted EPS was $-0.35. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $18.1M.
- Diluted EPS $-0.35.
- Sionna Therapeutics MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Sionna Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
Clinical-stage and growth biotech discuss trial milestones, cash runway, and partnership optionality.
Tailwinds
- Pipeline progress and data readouts.
- Cash runway from recent financings.
- Licensing or collaboration potential.
Headwinds
- Trial failure or regulatory delays.
- Dilution from equity raises.
- Commercialization timing uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q2 2025
-0.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+15.4%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+13.4%
Q2 2025
Best reaction
-11.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -11.3% | -12.4% | -21.8% | |
| Q4 2025 | -7.2% | -1.7% | +13.0% | |
| Q3 2025 | -1.6% | +0.4% | +13.0% | |
| Q2 2025 | +13.4% | +17.8% | +32.8% | |
| Q1 2025 | +4.7% | +9.0% | +40.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro